Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party

Background We analyzed the outcome of 100 patients with acquired severe aplastic anemia undergoing an alternative donor transplant, after immune suppressive therapy had failed. Design and Methods As a conditioning regimen, patients received either a combination of fludarabine, cyclophosphamide, and antithymocyte globulin (n=52, median age 13 years) or this combination with the addition of low dose (2 Gy) total body irradiation (n=48, median age 27 years). Results With a median follow-up of 1665 and 765 days, the actuarial 5-year survival was 73% for the group that received fludarabine, cyclophosphamide, and antithymocyte globulin and 79% for the group given the conditioning regimen including total body irradiation. Acute graft-versus-host disease grade III–IV was seen in 18% and 7% of the groups, respectively. Graft failure was seen in 17 patients with an overall cumulative incidence of 17% in patients receiving conditioning with or without total body irradiation: 9 of these 17 patients survive in the long-term. The most significant predictor of survival was the interval between diagnosis and transplantation, with 5-year survival rates of 87% and 55% for patients grafted within 2 years of diagnosis and more than 2 years after diagnosis, respectively (P=0.0004). Major causes of death were graft failure (n=7), post-transplant-lymphoproliferative-disease (n=4) and graft-versus-host disease (n=4). Conclusions This study confirms positive results of alternative donor transplants in patients with severe aplastic anemia, the best outcomes being achieved in patients grafted within 2 years of diagnosis. Prevention of rejection and Epstein-Barr virus reactivation may further improve these results.

• Publication year

  2010

• Venue

  Haematologica

• Publication date

  2010-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3324/haematol.2009.018267PMID 20494932PMCID PMC2878797
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fludarabine, cyclophosphamide, anti‐thymocyteglobulin, and low‐dose total body irradiation conditioning enables 1‐HLA‐locus‐mismatched hematopoietic stem cell transplantation for very severe aplastic anemia without affecting ovarian function

  2009cited by this paper
• Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD.

  2009cited by this paper
• Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen

  2009cited by this paper
• Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA

  2009cited by this paper
• Rituximab Prophylaxis of EBV Reactivation after Alternative Donor Transplants Following Anti-Thymocyte Globulin-Based Conditioning Regimens.

  2008cited by this paper
• Recent improvement in outcome of unrelated donor transplantation for aplastic anemia

  2008cited by this paper
• Outcome of unrelated donor stem cell transplantation for children with severe aplastic anemia

  2008cited by this paper
• Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient.

  2007cited by this paper
• Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia

  2007cited by this paper
• Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia.

  2007cited by this paper
• Overcoming graft rejection in heavily transfused and allo‐immunised patients with bone marrow failure syndromes using fludarabine‐based haematopoietic cell transplantation

  2006cited by this paper
• Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia

  2006cited by this paper
• Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine‐based preparative regimen

  2006cited by this paper
• Allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia following nonmyeloablative conditioning using 200-cGy total body irradiation and fludarabine.

  2006cited by this paper
• Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party

  2005cited by this paper
• Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program.

  2002influential reference
• Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation.

  2001influential reference
• Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin.

  1997cited by this paper
• Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group.

  1994influential reference
• Secondary solid malignant tumors occurring after bone marrow transplantation for severe aplastic anemia given thoraco-abdominal irradiation.

  1994cited by this paper

• Development and Validation of the PASS Score: A Simplified Tool to Diagnose Acquired Aplastic Anemia in Adults

  2026cites this paper
• Excellent Outcomes in Feasibility Study of Radiation-free Conditioning and Transplant in Pediatric Severe Aplastic Anemia.

  2025cites this paper
• Unrelated donor transplantation for relapsed refractory aplastic anemia, with quadruple GvHD prophylaxis

  2025cites this paper
• Early withdrawal immunosuppression improved mixed chimerism in stem cell transplantation for pediatric aplastic anemia

  2025cites this paper
• Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice

  2025cites this paper
• Efficacy and safety of ruxolitinib combined with steroids for first-line treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: a single-center, real-world experience

  2025cites this paper
• Comparative study of Bu/Cy/ATG and Flu/Cy/ATG conditioning regimens for unrelated donor hematopoietic stem cell transplantation in severe aplastic anemia.

  2025cites this paper
• Chinese Society of Hematology clinical practice guidelines for the comprehensive management of allogeneic hematopoietic stem cell transplantation in patients with severe aplastic anemia

  2025cites this paper
• Outcomes of allogeneic hematopoietic stem cell transplantation for acquired pure red cell aplasia.

  2025cites this paper
• Donor impact on allogeneic transplant outcomes with PTCy for severe aplastic anemia: a study of the SAAWP EBMT

  2025cites this paper
• Outcomes of hematopoietic stem cell transplantation using melphalan-based conditioning in children with acquired aplastic anemia

  2025cites this paper
• Outcomes of Matched Sibling and Haploidentical Donors Hematopoietic Stem Cell Transplantation for Pediatric Severe Aplastic Anemia: A Retrospective Multicenter Study.

  2025cites this paper
• Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline

  2024cites this paper
• Co-transplantation of umbilical cord mesenchymal stem cells and peripheral blood stem cells in children and adolescents with refractory or relapsed severe aplastic anemia

  2024cites this paper
• Long-term survival after unrelated donor marrow transplantation for aplastic anaemia after optimized conditioning regimen: a retrospective multicentre cohort study

  2024cites this paper
• Successful Treatment of Severe Aplastic Anemia with Hematopoietic Stem Cell Transplantation in the Setting of Active Mucormycosis

  2024cites this paper
• Febuxostat-induced agranulocytosis in a pediatric hematopoietic stem cell transplant recipient: Case Report and literature review

  2024cites this paper
• First-line treatment of severe aplastic anemia: immunosuppressive therapy plus eltrombopag versus haploidentical hematopoietic stem cell transplantation, a multicenter prospective study

  2024cites this paper
• Choosing donors in clinical practice.

  2024cites this paper
• Aplastic Anemia: Demographic and Clinical Characteristics in Costa Rica

  2024cites this paper
• Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP).

  2024cites this paper
• Combating bone marrow failure with polymer materials.

  2024cites this paper
• The state of the art in the treatment of severe aplastic anemia: immunotherapy and hematopoietic cell transplantation in children and adults

  2024cites this paper
• Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT.

  2024cites this paper
• Treatment of relapsed/refractory severe aplastic anemia in children: Evidence‐based recommendations

  2024cites this paper
• Recent advances in the diagnosis and treatment of pediatric acquired aplastic anemia

  2023cites this paper
• Prospective study of a modified posttransplant cyclophosphamide regimen for severe aplastic anemia patients with HLA-haploidentical transplantation.

  2023cites this paper
• Donor specific anti-HLA antibodies in hematopoietic stem cell transplantation. Single Center prospective evaluation and desensitization strategies employed

  2023cites this paper
• Efficacy of hematopoietic stem cell transplantation in the treatment of children with non‐severe aplastic anemia

  2022cites this paper
• Primary graft failure following allogeneic hematopoietic stem cell transplantation: risk factors, treatment and outcomes

  2022cites this paper
• Survival and stability of blood chimerism in CBA mice after bone marrow transplantation from donors of various origin carrying the EGFP gene

  2022cites this paper
• Comparisons of unmanipulated haploidentical donor, unrelated cord blood donor and matched unrelated donor hematopoietic stem cell transplantation in pediatric acquired severe aplastic anemia: a single center study

  2022cites this paper
• Fludarabine/Cyclophosphamide Conditioning Regimen in Aplastic Anemia Patients Receiving Matched-Sibling Donor Transplant Is Non-inferior to ATG/Cyclophosphamide: A Single-Center Experience from Pakistan

  2022cites this paper
• Treatment outcome of 301 aplastic anemia patients in China: a 10-year follow-up and real-world data from single institute experience

  2021cites this paper
• Development and validation of a mortality predicting scoring system for severe aplastic anaemia patients receiving haploidentical allogeneic transplantation

  2021cites this paper
• An Antithymocyte Globulin-Free Conditioning Regimen Using Fludarabine and Cyclophosphamide Is Associated with Good Outcomes in Patients Undergoing Matched Related Family Donor Transplantation for Aplastic Anemia.

  2021cites this paper
• Safety and Efficacy of Co-transplantation of Hematopoietic Stem Cells Combined With Human Umbilical Cord-Derived Mesenchymal Stem Cells in Children With Severe Aplastic Anemia: A Single-Center Experience.

  2021cites this paper
• Total body irradiation-containing conditioning regimens without antithymocyte globulin in adults with aplastic anemia undergoing umbilical cord blood transplantation

  2021cites this paper
• A comparative study of porcine antihuman lymphocyte globulin versus antithymocyte globulin-fresenius in an allogeneic hematopoietic cell transplantation conditioning regimen for severe aplastic anemia

  2021cites this paper
• Mixed chimerism after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia

  2021cites this paper
• Fludarabine–Cyclophosphamide-Based Conditioning with Antithymocyte Globulin Serotherapy Is Associated with Durable Engraftment and Manageable Infections in Children with Severe Aplastic Anemia

  2021cites this paper
• A modified conditioning regimen based on low‐dose cyclophosphamide and fludarabine for haploidentical hematopoietic stem cell transplant in severe aplastic anemia patients at risk of severe cardiotoxicity

  2021cites this paper
• Optimizing conditioning regimen with low-dose irradiation or busulfan enables the outcome of transplantation from a 6–7/8 HLA-matched donor comparable to that from an 8/8 HLA-matched unrelated donor in severe aplastic anemia patients under 40 years

  2021cites this paper
• Outcomes of alternative hematopoietic stem cell transplantation in pediatric aplastic anemia High Failure-free Survival after Unrelated Donor Peripheral Blood Stem Cell Transplantation in Pediatric Severe Aplastic Anemia.

  2021cites this paper
• Fludarabine, Campath and Low dose Cyclophosphamide (FCClow) with or without TBI Conditioning Results in Excellent Transplant Outcomes in Children with Severe Aplastic Anemia.

  2020cites this paper
• Mixed chimerism and secondary graft failure in allogeneic hematopoietic stem cell transplantation for aplastic anemia.

  2020cites this paper
• Risk factors for secondary poor graft function after bone marrow transplantation in children with acquired aplastic anemia

  2020cites this paper
• Impact of CD34 cell dose and conditioning regimen on outcomes after Haploidentical donor hematopoietic stem cell transplantation with post-transplant cyclophosphamide for relapsed/refractory severe aplastic anemia: Haploidentical HCT with PTCy for SAA.

  2020cites this paper
• Posttransplantation Lymphoproliferative Disease Treated by Retransplantation

  2020cites this paper
• A case series of post-transplant cyclophosphamide in unrelated donor hematopoietic transplantation for aplastic anemia.

  2020cites this paper
• Conditioning regimen for allogeneic bone marrow transplantation in children with acquired bone marrow failure: fludarabine/melphalan vs. fludarabine/cyclophosphamide

  2020cites this paper
• Comparison of efficacy and health-related quality of life of first-line haploidentical hematopoietic stem cell transplantation with unrelated cord blood infusion and first-line immunosuppressive therapy for acquired severe aplastic anemia

  2020cites this paper
• Successful treatment with matched unrelated donor peripheral blood stem cell transplantation for very severe aplastic anemia in presence of active infections

  2020cites this paper
• Long-term outcome after allogeneic hematopoietic stem cell transplantation for Shwachman–Diamond syndrome: a retrospective analysis and a review of the literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation (SAAWP-EBMT)

  2020cites this paper
• Bendamustine with total body irradiation conditioning yields tolerant T-cells while preserving T-cell-dependent graft-versus-leukemia

  2020cites this paper
• Comparable Outcomes Between Unrelated and Haploidentical Stem Cell Transplantation in Adult Patients With Severe Aplastic Anemia.

  2020cites this paper
• Better Failure-Free Survival and Graft-versus-Host Disease-Free/Failure Free Survival with Fludarabine-Based Conditioning in Stem Cell Transplantation for Aplastic Anemia in Children

  2020cites this paper
• High Overall and GVHD-Free Survival in Patients with Aplastic Anemia Receiving in vivo T-cell Depletion Transplants and Long-Term Complications.

  2020cites this paper
• Allogeneic Hematopoietic Stem Cell Transplant Offer Good Outcomes in Pediatric Aplastic Anemia: Experience From Developing World.

  2020cites this paper
• Cyclosporine/methotrexate versus tacrolimus/methotrexate with or without anti-thymocyte globulin as GVHD prophylaxis in adult patients with aplastic anemia

  2020cites this paper
• Acquired Aplastic Anemia

  2020cites this paper
• A single institution experience of total lymphoid irradiation using helical tomotherapy as part of the conditioning regimen of transplantation for severe aplastic anemia patients

  2020cites this paper
• Immune responses post haematopoietic stem cell transplant : clinical studies of vaccination and autoimmunity

  2019cites this paper
• Efficacy of Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation for 40 Cases with Severe Aplastic Anemia

  2019cites this paper
• The Case for Upfront HLA-Matched Unrelated Donor Hematopoietic Stem Cell Transplantation as a Curative Option for Adult Acquired Severe Aplastic Anemia.

  2019cites this paper
• Management of acquired aplastic anemia in children : A single center experience.

  2019cites this paper
• Unrelated cord blood transplantation for severe aplastic anemia using intensified immunoablative conditioning regimen leading to high engraftment and survival

  2019cites this paper
• Sequential transplantation and implications for clinical management: OLT followed by HCT and consequent RT in a pediatric patient

  2019cites this paper
• Hematopoietic stem cell transplantation for non-malignant hematological disorders.

  2019cites this paper
• Integrated analysis of global gene and microRNA expression profiling associated with aplastic anaemia.

  2019cites this paper
• Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre‐transplant conditioning using fludarabine, reduced‐dose cyclophosphamide, and low‐dose thymoglobulin: A KSGCT prospective study

  2019influential citation
• Aplastic Anemia Preconditioned with Fludarabine, Cyclophosphamide, and Anti-Thymocyte Globulin

  2019cites this paper
• Bendamustine with Total Body Irradiation Limits Murine Graft-versus-Host Disease in Part Through Effects on Myeloid-Derived Suppressor Cells.

  2019cites this paper
• High graft-versus-host disease-free, relapse/rejection-free survival and similar outcome of related and unrelated allogeneic stem cell transplantation for aplastic anemia - a nationwide Swedish cohort study.

  2019cites this paper
• Autologous cord blood transplantation in children with acquired severe aplastic anemia

  2018cites this paper
• Allogeneic Matched Related Donor Bone Marrow Transplantation for Pediatric Patients With Severe Aplastic Anemia Using “Low-dose” Cyclophosphamide, ATG Plus Fludarabine

  2018cites this paper
• IMPACT OF T-CELL DEPLETION STRATEGIES ON OUTCOMES FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR IDIOPATHIC APLASTIC ANEMIA: A STUDY ON BEHALF OF THE EUROPEAN BLOOD AND MARROW TRANSPLANT (EBMT) SAA WORKING PARTY

  2018cites this paper
• Alternative donor transplants for severe aplastic anemia.

  2018cites this paper
• Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Achieved Outcomes Comparable With Matched Unrelated Donor Transplantation in Young Acquired Severe Aplastic Anemia.

  2018cites this paper
• Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis

  2018influential citation
• Outcomes of a novel rituximab-based non-myeloablative conditioning regimen for hematopoietic cell transplantation in severe aplastic anemia

  2018cites this paper
• Updated Guidelines for the Treatment of Acquired Aplastic Anemia in Children

  2018cites this paper
• Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation.

  2018cites this paper
• Preparing the Patient for HSCT: Conditioning Regimens and Their Scientific Rationale

  2018cites this paper
• Aplastic Anemia-Diagnostics and Therapy of Acquired Aplastic Anemia

  2018cites this paper
• Recent advances and current challenges in allogeneic stem cell transplantation in patients with acquired severe aplastic anemia

  2018cites this paper
• Impact of T‐cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party

  2018cites this paper
• Aplastic anemia and cytotoxic T lymphocyte antigen-4 haploinsufficiency treated with bone marrow transplantation.

  2017cites this paper
• Outcome of Second Transplantation Using Umbilical Cord Blood for Graft Failure after Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia.

  2017cites this paper
• Improved outcome of haploidentical transplantation in severe aplastic anemia using reduced-intensity fludarabine-based conditioning

  2017cites this paper
• Benign hematolojik hastalıklarda hematopoetik kök hücre nakli

  2017cites this paper
• Hematological Disorders in Children

  2017cites this paper
• Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000–2011

  2017cites this paper
• How I treat acquired aplastic anemia.

  2017cites this paper
• Aplastic anemia and paroxysmal nocturnal hemoglobinuria

  2017cites this paper
• Hematopoietic cell transplantation for aplastic anemia

  2017cites this paper
• Fludarabine-based reduced intensity regimen for matched related donor hematopoietic stem cell transplantation in acquired severe aplastic anemia.

  2017cites this paper
• Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study.

  2017cites this paper
• Unrelated cord blood transplantation in aplastic anemia: is anti-thymocyte globulin indispensable for conditioning?

  2017cites this paper
• 7 – Aplastische Anämien

  2017cites this paper